Provided by Tiger Trade Technology Pte. Ltd.

Evolent Health

2.21
-0.1700-7.14%
Post-market: 2.240.0300+1.36%19:57 EDT
Volume:2.21M
Turnover:4.93M
Market Cap:246.64M
PE:-0.44
High:2.35
Open:2.35
Low:2.19
Close:2.38
52wk High:12.07
52wk Low:2.19
Shares:111.60M
Float Shares:86.94M
Volume Ratio:0.59
T/O Rate:2.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0732
EPS(LYR):-5.0732
ROE:-66.54%
ROA:-0.12%
PB:0.59
PE(LYR):-0.44

Loading ...

Evolent Reports Inducement Award Under Nyse Listing Rule 303a.08

THOMSON REUTERS
·
Jan 03

Syra Health Names Gregory R. Alexander as CEO

Reuters
·
Dec 18, 2025

Evolent Health Inc. Files Initial Beneficial Ownership Statement for Director Jill D. Smith

Reuters
·
Dec 13, 2025

Evolent Health Closes Privia Management Company Acquisition

Reuters
·
Dec 08, 2025

Evolent Health Inc : Piper Sandler Cuts Target Price to $6 From $18

THOMSON REUTERS
·
Dec 02, 2025

Evolent Health Inc - Reaffirms Q4 2025 Revenue Guidance - SEC Filing

THOMSON REUTERS
·
Dec 02, 2025

Evolent Health Inc - Reaffirms Q4 2025 Adj Ebitda Guidance - SEC Filing

THOMSON REUTERS
·
Dec 02, 2025

Evolent Health Announces Retirement of Director Cheryl Scott and Appointment of Independent Director Smith

Reuters
·
Dec 02, 2025

Canaccord Genuity Keeps Their Buy Rating on Evolent Health (EVH)

TIPRANKS
·
Nov 25, 2025

Evolent Health Is Maintained at Buy by Citigroup

Dow Jones
·
Nov 22, 2025

Director’s Bold Move: Major Stock Purchase Signals Confidence in Evolent Health

TIPRANKS
·
Nov 20, 2025

Evolent Health Director Brendan B. Springstubb Reports Acquisition of Common Shares

Reuters
·
Nov 20, 2025

Evolent Health Q3 Revenue USD 479.533 Million Vs. IBES Estimate USD 467.5 Million

Reuters
·
Nov 20, 2025

Evolent Health Is Maintained at Overweight by JP Morgan

Dow Jones
·
Nov 18, 2025

Evolent Health Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Nov 15, 2025

Canaccord Genuity Sticks to Its Buy Rating for Evolent Health (EVH)

TIPRANKS
·
Nov 14, 2025

Evolent Health (EVH) Gets a Buy from BTIG

TIPRANKS
·
Nov 14, 2025

Evolent Health Inc : Canaccord Genuity Cuts Target Price to $9 From $16

THOMSON REUTERS
·
Nov 14, 2025

Evolent Health: Strong Growth Prospects and Strategic Market Positioning Justify Buy Rating

TIPRANKS
·
Nov 14, 2025

Evolent Health: Positioned for Growth with Strong Fundamentals and Valuation Upside

TIPRANKS
·
Nov 13, 2025